Fig. 5From: Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M mattersPatterns of treatment failure. The distribution of tumor sites with initial progressive disease after first-line EGFR-TKIs treatment failure were generally similar among the three groups, except for brain progressionBack to article page